1. Generics Bulletin
  2. >>Products
  3. >>Generics

Endo Reiterates US Generics Environment Is ‘Challenging’

Follows Recent Comments By Sandoz And Teva

 
• By Dean Rudge

Endo’s non-injectable Generics revenues plunged by 28% in Q1, in part due to competitive challenges in the US generics sector that management said would continue through 2021.

chart
Endo sees a "fair amount of competition impact" in 2021 • Source: Shutterstock

Endo International plc says its outlook for the company’s portfolio of non-injectable generic products in the US “is a challenging one for 2021,” amid growing debate over competition and pricing trends.

During the company’s Q1 earnings call, president and CEO Blaise Coleman was asked to comment on “mixed data points [seen...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products